Lung adenocarcinoma (LUAD) remains one of the leading causes of death in 51 patients with cancer. The association of CD155 with CD96 transmits an 52 inhibitory signal and suppresses antitumor immune response. This study 53 investigates the effect of CD155/CD96 on immune suppression in LUAD. We 54 demonstrate that LUAD patients with high CD155 expression suffer from 55 immune suppression and experience a poor prognosis, which coincides with 56 an inhibited AKT-mTOR signaling pathway in CD8 T cells and subsequently 57 up-regulated CD96 expression. Moreover, the inhibition effect can be 58 reversed by CD96 blocking antibody. High CD155 expression inhibited the 59 release of IFNγ from CD8 cells. Moreover, Blocking CD96 restored IFNγ 60 production in CD8 T cells and neutralized the inhibition of IFNγ production in 61 CD8 T cells mediated by CD155. Animal experiments showed that CD155-62 mediated LUAD growth might depend on its suppression antitumor immune 63 response in the tumor microenvironment in PDX mice. In conclusion, our 64 results suggest that LUAD cells suppress antitumor immune response in the 65 tumor microenvironment through CD155/CD96. CD155/CD96 could be a 66 potential therapeutic target for LUAD patients. 67 68
49
Introduction 87
Lung cancer is the leading cause of death among cancer patients. 88
More than 1 million deaths are related to lung cancer annually (Ding et al, 89 2008) , and approximately 1.2 million new lung cancer cases are diagnosed 90 each year (Jemal et al, 2011) . Lung adenocarcinoma (LUAD) is the most 91 common type of non-small cell lung cancer (NSCLC) . Surgery remains the 92 first-line treatment and the most successful option in located disease of LUAD 93 (Molina et al, 2008) . Despite a decline in the cancer death rate over the past 94 two decades, LUAD has a 5-year survival rate of 10-15% in stage IV due to its 95 late-stage diagnosis and lack of effective therapeutic options (Imielinski et al, 96 2012) . 97
Immune escape represents the failure of the immune system in 98 preventing carcinogenesis (Kim et al, 2007; Swann & Smyth, 2007) . The 99 tumor microenvironment is composed of regulatory T cells, tumor-associated 100 macrophages and myeloid-derived suppressor cells (MDSCs) (Noy & Pollard, 101 2014; Sato et al, 2005; Talmadge & Gabrilovich, 2013) , which are the 102 signature of chronic inflammation and immune suppression in the tumor milieu 103 (Crespo et al, 2013) . Recently, the development of cancer immunotherapy 104 that uses tumor-targeted monoclonal antibodies has achieved broad 105 therapeutic efficacy (Brahmer et al, 2012) . The application of monoclonal 106 antibody against PD-1/PD-L1 was associated with longer progression-free 107 and overall survival and fewer treatment-related adverse events than was 108 platinum-based combination chemotherapy in patients with previously 109 untreated advanced NSCLC (Herbst et al, 2016; Reck et al, 2016) . Given the 110 only 20-30% response rate of lung cancer when targeting PD-1/PD-L1, we 111 speculated that other molecules or mechanisms might be involved in limiting 112 the application of current immunotherapies for lung cancer patients. 113 CD155, a member of poliovirus receptor-related (PRR) family, was 114 initially identified as a receptor for poliovirus in humans (Mendelsohn et al, 115 1989) . The CD155 transcript is ubiquitously expressed in humans and mice 116 (Koike et al, 1990; Mendelsohn et al, 1989) . Recently, CD155 has been 117 identified as the ligand of the Ig-like receptors Tactile (CD96) and DNAM-1 118 (CD226) on T cells. The interaction of CD155 with CD96 transmits an 119 inhibitory signal. The interaction of CD155 with CD226 enhances the immune 120 response (Bottino et al, 2003; Shibuya et al, 1996; Yu et al, 2009) . Expression 121 of CD155 has been shown to be elevated in many types of tumors (Brooks et 122 al, 2017; Iguchi-Manaka et al, 2016) and is involved with immune suppression 123 in melanoma (Inozume et al, 2016) . Recently, CD96 -/mice displayed hyper-124 inflammatory responses, resulting in resistance to carcinogenesis and 125 experimental lung metastases (Chan et al, 2014) . Blocking CD96 can improve 126 tumor control in mice (Blake et al, 2016) . However, how CD155/CD96 is 127 involved in immune response in the tumor microenvironment of LUAD 128 remains unknown. 129
In the present study, we found that CD155 expression was increased in 130 tumor tissue and was associated with immune suppression in the tumor 131 microenvironment of LUAD. Blocking CD155/CD96 interaction restores CD8 T 132 cell effector functions by reversing CD8 T cell exhaustion, suggesting a 133 possible therapeutic role of CD155/CD96 in fighting LUAD. 134
135
Results 136
CD155 expression was associated with immune suppression in the 137 tumor microenvironment of LUAD 138
To investigate CD155 expression characteristics in LUAD tissues, we 139 first performed western blotting to compare its expression between tumor and 140 para-tumor lung tissues. We found that CD155 expression was substantially 141 stronger in LUAD tissues than that in para-tumor normal lung tissues (Figure 142 1A) . The increased CD155 expression in LUAD tissues was confirmed by IHC 143 ( Figure 1B ). Lung adenocarcinoma cells (LUADCs) were isolated from tumor 144 tissues in 6 CD155 high and 6 CD155 low LUAD patients using NanoVelcro as 145 described previously (Lin et al, 2014) ( Figure S1 ). The primary LUADCs 146 isolated from tumor tissues were also CD155 positive as measured by 147 immunofluorescence ( Figure 1C ). Further, CD155 high expression in tumor 148 tissues predicted a poor prognosis in LUAD ( Figure S2 ). CD155, as the 149 molecule of a co-inhibitory pathway, suppresses the anti-melanoma immune 150 response (Inozume et al, 2016) . We speculate that the low survival rate in 151 CD155 high patients might be due to the immune suppression in the tumor 152 microenvironment mediated by CD155. 153
To further explore the involvement of CD155 in the antitumor immune 154 response in LUAD, we first studied the association of CD155 with the immune 155 response in the tumor microenvironment of LUAD. CD155 high and CD155 low 156
were identified according to its expression intensity as described in the 157 methods section ( Figure 1D ). We found that the transcripts of inhibitory 158 molecules, such as CD96, TIGIT, Pdcd1 and Lag-3, were substantially higher 159 in CD155 high patients, while CD226 was lower in CD155 high patients ( Figure  160 1E and S3). In contrast, gene expression of T cell effector function-associated 161 molecules was essentially lower in 13 CD155 high patients compared with that 162 in 11 CD155 low patients ( Figure 1E 
LUADCs impaired the effector functions of CD8 T cells through direct 167

cell-cell contact 168
Tumor-infiltrating lymphocytes (TILs) predict a better prognosis in 169 patients with colorectal cancer (Pages et al, 2005) . Here, we showed that a 170 high density of CD8 T cell infiltration was associated with better survival in 171 patients with LUAD ( Figure S4 ), which was in accordance with a previous 172 report (Kawai et al, 2008) . CD8 T cells are the effector cells in antitumor 173 immune response. However, TILs are functionally exhausted in the tumor 174 microenvironment, which has not fully been understood yet. To elucidate how 175 cancer cells influence CD8 T cells in the tumor microenvironment, we first 176 performed a cell-cell contact co-culture of CD8 T cells (from the same 177 CD155 high LUAD patient) and LUADCs (from 6 independent CD155 high 178 patients) in vitro ( Figure 2A ). We found that GzmB (granzyme B) and Perforin 179 expression on CD8 T cells was inhibited, as measured by flow cytometry, 180 when co-cultured with LUADCs ( Figure 2B -E). Further, production of IL-2 181 (Interleukin-2), TNFα (tumor necrosis factor-alpha) and IFNγ cytokines in CD8 182 T cells was also suppressed ( Figure 2F -I). However, cytokine production was 183 not affected when we separately cultured the T cells (from the same 184 CD155 high LUAD patient) and LUADCs (from 6 independent CD155 high 185 patients) using a cell culture insert with a 0.4-μm pore size ( Figure 2J in the tumor microenvironment [21] . To confirm the hypothesis that CD155 193 might be involved in T cell inhibition mediated by LUADCs, we first 194 determined CD155 expression in LUADC1-6 by western blotting. Compared 195 with CD155-low level in BEAS-2B cells, LUADC1-6 cells appear CD155-high 196 ( Figure 3A ). CD155 expression in LUADCs was further confirmed by flow 197 cytometry ( Figure 3B) . In a T cell-cancer cell co-culture system ( Figure 3C 
CD155-independent tumor growth in LUADCs 213
CD155 was stably downregulated in LUADCs (from 6 independent 214 CD155 high patients) or overexpressed in LUADCs (from 6 independent 215 CD155 low patients). Knockdown or overexpression was confirmed by western 216 blotting and flow cytometry ( Figure S5 ). We found that neither knockdown nor 217 overexpression of CD155 affected cancer cell proliferation, as measured by 218 cell number ( Figure S6A-B ). We used PI (Propidium Iodide) to investigate the 219 cell cycle by flow cytometry and observed that CD155 knockdown did not 220 change the cell cycle distribution of cancer cells. Further, CD155 221 overexpression showed no effects on the cell cycle ( Figure S6C -E). To study 222 whether tumor growth was affected by CD155 in vivo, we utilized non-invasive 223 imaging. LUADCs were stably transfected with luciferase and inoculated into 224 NOG mice subcutaneously. The data showed no difference in tumor growth 225 between mice that received LUADCs-vector or LUADCs-CD155 cells ( The tumor microenvironment is infiltrated with tumor-associated 231 macrophages, myeloid-derived suppressor cells and regulatory T cells 232 (Hanahan & Weinberg, 2011) . The stromal cells also play critical roles in 233
shaping the tumor microenvironment (Hanahan & Coussens, 2012) . To better 234 duplicate the tumor microenvironment similar to LUAD patients, we used a 235 PDX mouse model as described in the method section to study the immune 236 response in the tumor microenvironment. Previous study shows that 237 CD155/96 is important for NK cells in antitumor immune response. In this 238 mouse model, the CD56+ NK cells were sorted out from the injected PBMC 239 (from 6 independent CD155 low patients), excluding the antitumor effects by NK 240 cells. To investigate whether CD155/CD96 affects immune reaction and tumor 241 growth, PDX mice were treated with rCD155 or vehicle ( Figure 4A ). We first 242 confirmed the binding of rCD155 to CD96 and that decreased IFNγ production 243 in CD8 T cells ( Figure S7 ). The infiltration of CD8 T cells in the tumor 244 microenvironment was decreased to some extent by rCD155 treatment as 245 measured by IHC ( Figure 4B -C). To measure the effector function of the 246 tumor infiltrated CD8 T cells, CD8 T cells were isolated from the tumor tissue 247 and measured IFNγ production by flow cytometry. rCD155 treatment 248 decreased IFNγ production in CD8 T cells isolated from tumor tissue ( Figure  249 4D-E). The IFNγ transcript was also decreased by rCD155 treatment as 250 measured by RT-PCR ( Figure 4F ). To further understand the functional status 251 of CD8 T cells in the tumor microenvironment, we measured TNF-α, GzmB 252 and Perforin expression in the tumor microenvironment by RT-PCR. We found 253 that rCD155 treatment decreased TNF-α, GzmB and Perforin expression in 254 the tumor microenvironment ( Figure 4G ). Importantly, rCD155 treatment 255 promoted tumor growth in the PDX mice ( Figure 4H ). 256
To further investigate the function of CD155 on immune response in 257 the tumor microenvironment of LUAD, CD155 was stably overexpressed in 258 LUADC cells (from 6 independent CD155 low patients). Cells were inoculated 259 into NOG mice subcutaneously. The mice were subsequently reconstituted 260 with or without human PBMCs. We found that tumors in NOG mice that 261 lacked human PBMC reconstitution grew substantially faster than those in 262 mice carrying a human immune system ( Figure S8A-B ). Further, in mice 263 reconstituted with human PBMCs, tumor growth was substantially faster in 264 mice that received LUADC-CD155 cells than in those that received LUADC-265 vector cells ( Figure S8C -D). Moreover, mice that received LUADC-CD155 266 cells showed a poorer prognosis than those that received LUADC-vector cells 267 ( Figure S8E ). 268
Therefore, these results demonstrated that CD155-mediated LUAD 269 growth might depend on its suppression antitumor immune response in the 270 tumor microenvironment. CD96, as a co-inhibitory molecule, competes with the co-stimulatory 275 molecule of CD226 for binding to CD155. The lost balance between these two 276 molecules might lead to a hypo-or hyper-immune response. We found that 277 CD8 T cells from LUAD patients expressed higher levels of CD96 compared 278 with healthy controls (HC). CD96 expression was even higher in TILs than in 279 T cells from the circulation ( Figure 5A-B ). CD226 expression was substantially 280 lower in T cells from LUAD patients than that in HC. CD226 expression in 281
TILs was further decreased compared with that from the circulation ( Figure  282 5C-D). The phosphorylation of AKT and mTOR was lower in CD96 + CD8 T 283 cells from LUAD patients than that in CD96 -CD8 T cells. The phosphorylation 284 of mTOR downstream molecules also decreased in CD96 + cells compared 285
with that in CD96cells, as measured by flow cytometry and western blotting 286 The tumor microenvironment is infiltrated with exhausted T cells 297 (Crespo et al, 2013; Jiang et al, 2015) . CD96, a recently identified co-298 inhibitory molecule that competes with CD226 for the ligand CD155, was 299 increased on CD8 T cells in the LUAD tumor microenvironment (Chan et al, 300 2014) . To determine how CD96 expression on CD8 T cells is regulated in the 301 tumor microenvironment by cancer cells, we performed cell-cell contact T cell-302 cancer cell co-culture as described above and found that CD96 expression on 303 CD8 T cells was increased when co-cultured with CD155 high cancer cells 304 (from 6 independent CD155 high patients) ( Figure 6A ), whereas the co-305 stimulatory receptor CD226 was inhibited by CD155 high cancer cells ( Figure  306 6B). As shown in Figure 3D , AKT-mTOR pathway in CD8 T cells was inhibited 307 by culturing with CD155 high cancer cells. We found that blocking CD96 can 308 rescue the inhibition. The phosphorylation of AKT-mTOR was increased by 309 blocking CD96 as measured by western blot ( Figure 6C ). Also, the 310 phosphorylation of 6SK and 4EBP1, which are downstream molecules of 311 mTOR, was also increased in CD8 T cells when CD96 was blocked, as 312 measured by flow cytometry ( Figure 6D ). Blocking CD96 in the T cell-cancer 313 cell co-culture system increased IFNγ production in CD8 T cells ( Figure 6E ). 314
IFNγ production in CD8 T cells was decreased when co-cultured with 315 CD155 high LUAD cells, which was further decreased when CD155 was 316 overexpressed in CD155 high LUAD cells ( Figure 6F ). However, CD96 317 blockade could neutralize the inhibition mediated by CD155 expression 318 ( Figure 6F ). Thus, LUAD cells suppress the T cell response through 319 CD155/CD96 signaling in the tumor microenvironment. 320 321 Discussion 322
In the tumor microenvironment, the upregulation of negative signals on 323 T-cell responses suppresses the antitumor immune response and promotes 324 tumor progression (Zou & Chen, 2008) . In this study, we showed that CD155 325 expression was increased in LUAD tumor tissue, and LUAD cells suppressed 326 the immune response in the tumor microenvironment through CD155/CD96. 327
However, CD155 itself showed no effects on cancer cell proliferation in vitro 328 or tumor growth in vivo. 329 CD8 T cells are the effector cells in the antitumor immune response in 330 most tumor models (Rosenberg et al, 2004) . However, T cells that have 331 infiltrated into the tumor microenvironment are exhausted and functionally 332 impaired (Ahmadzadeh et al, 2009; Jiang et al, 2015) . In the current study, we 333 found that LUAD cells impaired the effector functions of CD8 T cells through 334 cell-cell contact, which explained the immune suppression in the tumor 335 microenvironment. In addition to tumor-associated macrophages, MDSC and 336 regulatory T cells, cancer cells can impair CD8 T cell functions directly and 337 escape immune attack. 338 CD155 functions as a cell adhesion molecule that enhances glioma cell 339 migration (Sloan et al, 2005) , and its expression is increased at the RNA and 340 protein levels in tumor tissues (Chandramohan et al, 2017; Masson et al, 341 2001) . The association of CD155 to TIGIT (T cell immunoreceptor with Ig and 342 ITIM domains) transmits a negative signal to T cells and suppresses immune 343 response (He et al, 2017 ). In the current study, we found that CD155 344 expression was significantly increased in LUAD tissue. The primary LUAD 345 cells isolated from patients with LUAD expressed high levels of CD155, which 346 correlated with immune suppression in the tumor microenvironment. The 347 CD155-associated hypo-immune response in the tumor microenvironment of 348 LUAD could lead to immune invasion and promote tumor growth. In addition, 349 CD155 high patients showed poorer survival than CD155 low patients, which was 350 in accordance with a previous report (Atsumi et al, 2013) . Interestingly, we 351 found that CD155 expression did not affect cancer cell proliferation in vitro or 352 tumor growth in vivo. Further, tumor growth was greater in NOG mice without 353 a human immune system than in mice with a reconstituted human immune 354 system. CD155 overexpression in cancer cells resulted in greater tumor 355 growth and poorer survival in tumor-bearing NOG mice reconstituted with 356 human immune system. CD155 promoted tumor growth in mice reconstituted 357 with the human system through limiting the immune response in the tumor 358 microenvironment. These data further suggest that CD155 mediates LUAD 359 progression by manipulating the immune system, which is independent of 360 cancer cell proliferation. 361
To better understand how CD155 regulates the immune response 362 mediated by CD8 T cell in the tumor microenvironment, we established a PDX 363 model using patient-derived tumor tissues and reconstituted the mice with 364 PBMC from the same donors. To exclude the anti-tumor effect mediated by 365 CD56+ NK cells, CD56+ NK cells in PBMC were sorted out before injection. 366
We found that rCD155 treatment decreased CD8 T cell in the tumor 367 microenvironment and IFNγ production in the infiltrated CD8 T cells was 368 decreased by rCD155. In addition, rCD155 decreased the transcripts of IFNγ, 369 TNF-α, GzmB and Perforin in the tumor tissue. The suppressed immune 370 response contributed to tumor growth in the PDX mice. Thus, enhancing the 371 antitumor immune response targeting CD155 in the tumor microenvironment 372 could be a good therapeutic strategic for LUAD. 373
The balance between the inhibitory signal CD96/CD155 and the co-374 stimulatory signal CD226/CD155 is important for immune homeostasis (Chan 375 et al, 2014; Gao et al, 2017) . CD96 blockade inhibits experimental metastases 376 (Blake et al, 2016) and prevents tumor from relapsing in a transgenic 377 pancreatic ductal adenocarcinoma mouse model (Brooks et al, 2017) . In the 378 current study, we found that CD96 expression was increased in CD8 T cells 379 from LUAD patients. CD226, the co-stimulatory molecule, was decreased in 380 CD8 T cells from LUAD. The increased expression of CD96 and decreased 381 expression of CD226 contributed to a hypo-immune response, which impaired 382 the antitumor immune response in LUAD. The activity of AKT-mTOR signaling 383 was decreased in CD96+ CD8 T cells, implying the low activity of CD8 T cell 384 function. We confirmed this by measuring cytokine production in CD8 T cells. 385 CD96 + CD8 T cells expressed substantially lower levels of IFNγ and TNFα 386 than CD96 -CD8 T cells did. LUAD cells might suppress the immune response 387 by inducing the imbalance of CD96/CD226 expression on CD8 T cells in the 388 tumor microenvironment. 389
The tumor microenvironment has played a critical role in shaping the 390 immune response (Whiteside, 2008) . We showed that LUAD cells induced the 391 expression of CD96 and suppression of CD226 on CD8 T cells when they 392 were co-cultured together. Blocking CD96 restored CD8 T cell function as 393 inhibited by LUAD cells. LUAD cells impaired CD8 T cell function, and CD155 394 overexpression in cancer cells further decreased impaired CD8 T cell function. 395
Blocking CD96 neutralized CD155-mediated inhibition of CD8 T cells. LUAD 396 cells induced the imbalance between CD96 and CD226 expression on CD8 T 397 cells. These data demonstrated a mechanism in which LUAD cells suppress 398 immune response in the tumor microenvironment through CD155/CD96. 399
In conclusion, our findings provide insights into the mechanism that 400 CD155 facilitates tumor growth by impairing the antitumor immune response 401 in the tumor microenvironment through CD96. Targeting CD155/CD96 to 402 unleash CD8 T cells in the tumor microenvironment could be a novel 403 therapeutic alternative for LUAD patients. were obtained from each patient. Demographic characteristics of the included 417 patients were described in Supplementary Table 1 . 418 419
Cell lines and cell culture 420
The normal human bronchial epithelial cell line BEAS-2B was obtained 421 from ATCC (Maryland, USA). Cell lines were authenticated by cell viability 422 analysis, short tandem repeat (STR) profiling, and isoenzyme analysis. Cell 423 lines were screened for mycoplasma contamination as described previously 424 (Li et al, 2014) . Cells were grown in RPMI 1640 medium supplemented with 425 10% fetal bovine serum and kept in a humidified atmosphere at 37°C with 5% 426 counted from 5 different high-power areas. Protein expression levels were 455 evaluated semiquantitatively based on staining intensity and distribution using 456 the immunoreactive score (IRS) as described previously (Nagata et al, 2004) 457 as follows: IRS =SI (staining intensity) × PP (percentage of positive cells). The 458 SI was determined as follows: 0, negative; 1, weak; 2, moderate; and 3, 459 strong. The PP was defined as follows: 0, <1%; 1, 1%-10%; 2, 11%-50%; 3, 460 51%-80%; and 4, >80% positive cells. Ten visual fields from different areas of 461 each tumor were used for the IRS evaluation. Negative control slides were 462 included for each staining. An IRS score that reached 3.0 was recognized as 463 high expression; other scores were considered low expression in this study. 464 465
Reverse transcription-polymerase chain reaction (RT-PCR) 466
RNA was extracted according to the manufacturer's instructions 467 (Qiagen, USA). Taq DNA polymerase (Fermentas, USA) was used for cDNA 468 synthesis. Real-time PCR was performed using SYBR Green I (Roche, USA). 469
Amplification was performed as follows: preheating at 95°C for 10 min; 470 denaturing at 95°C for 15 s; and annealing and extension at 65°C for 45 s for 471 a total of 35 cycles. β-actin was used as control. The primers used are listed 472
in Supplementary Table 2 . 473 474
Flow cytometry 475
Cells isolated from tumor tissues, PBMCs isolated from the matched 476 patients with LUAD or healthy controls were stained with FITC-anti-CD4, PE-477 anti-CD8, APC-conjugated anti-CD96, PE-CY7-anti-Granzme B, APC-CY7-478 anti-Perforin, APC-anti-CD226 antibodies (Biolegend, USA). For intracellular 479 cytokine staining, T cells (1×10 6 cells/ml) were stimulated with 500 ng/ml 480 PMA and 1 μg/ml ionomycin at 37°C with 5% CO2, 1 μg/ml Brefeldin for 4 h. 481
Cells were collected and stained with BV650-conjugated anti-IFNγ antibody 482 (Biolegend, USA). The data were acquired using a cytometer machine (BD 483 Fortessa, USA). 484 485
Cell isolation 486
Fresh tumor tissue samples were obtained from patients with LUAD who 487 underwent surgical resection of tumor or from tumor-bearing mice. Samples 488 were minced and digested with type I collagenase (2 mg/ml) and DNase (40 489 U/ml) in RPMI 1640. Cells were filtered through a cell strainer and washed 490 with phosphate-buffered saline (PBS) twice. Peripheral blood mononuclear 491 cells (PBMCs) from the matched patients with LUAD were isolated by density 492 gradient centrifugation. Cells were first enriched for CD8 T cells using 493
EasySep™ human total or naïve CD8 T Cell enrichment kits (STEMCELL 494
Technologies, Vancouver, Canada). CD56and CD56 + PBMC fractions were 495 sorted by flow cytometry. Cells were checked for purity (>97%) by flow 496 cytometry. CD96 + and CD96 -CD8 T cells were sorted using BD influx, and 497 the purities were checked (>95%). 498 499 Plasmids and retroviral infection 500 CD155 constructs were generated by sub-cloning PCR-amplified full-501 length human CD155 cDNA into pcDNA3.1. Stable cell line (5×10 6 cells) 502 expressing CD155 was selected via treatment with 0.5 μg/ml puromycin for 10 503 days beginning 48 h after infection. Following selection, cancer cell lysates 504 prepared from the pooled cell populations in sampling buffer were fractionated 505 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 506
to detect protein levels via western blotting. To deplete CD155, shRNA 507 sequences were cloned into pGV248 to generate pGV248/CD155-shRNA 508 (containing a green fluorescent protein reporter gene) targeting CD155. A 509 negative vector (pGV248/control-shRNA) was similarly constructed with an 510 unrelated shRNA sequence. DNA sequencing was used to verify all inserted 511 sequences. Transduction efficiencies were confirmed by western blot. 512
Transduction efficiency is measured by flow cytometry and indicated as 513 percentage of successfully transduced GFP-positive cells. 514 515
Co-culture 516
To study CD8 T cell functions affected by cancer cells, CD8 T cells (1 517 ×10 6 cells/ml) were co-cultured with cancer cells (5×10 6 cells) in which 518 CD155 was either knocked down or overexpressed. Cells were stimulated 519 with anti-CD3/CD28 beads and co-cultured with cancer cells in 48-well plates 520 at a ratio of 5:1. Anti-CD3/CD28 beads were still present during T-cell/LUAD 521 co-culture. Human CD96 blocking antibody (5 μg/ml) or isotype control 522 independent CD155 low patients) were cut into 0.5-cm 3 pieces and 533 subcutaneously engrafted into the NOG mice. One week later, CD56 -PBMC 534 (1×10 7 cells/ml)) from the same donors were sorted by flow cytometry and 535 injected into the mice intraperitoneally. To study whether CD155 regulates 536 tumor growth in vivo, PDX mice were treated with recombinant human CD155 537 (rCD155, 5 mg/kg, R&D, USA) 3 times a week. 538
To further investigate the effect of CD155 on CD8 T cell immune 539 response in the tumor microenvironment, NOG mice received PBMC (1×10 7 540 cells/ml)) from the same patients intraperitoneally for immune reconstitution. 541 NOG mice were then subcutaneously inoculated with 5×10 6 LUADC-Vector or 542 LUADC-CD155 cells (from 6 independent CD155 low patients). 543
The mice were monitored every 2 days for signs of morbidity and 544 mortality. Tumor size was measured by a caliper, and tumor volume was 545 calculated using the formula volume as follow: (length×width 2 )×π/6. In vivo 546 bioluminescence imaging was performed using the IVIS100 system. The 547
Living Image acquisition and analysis software (Caliper Life Sciences) were 548 used together as described previously (Olsen et al, 2017) . 549 550
Statistics 551
The data were expressed as the mean±SEM. Statistical analyses were 552 performed using SPSS 16.0 (Chicago, IL, USA). The differences between 553 groups were assessed by an unpaired, two-tailed Student's t test. To adjust 554 for multiple testing, in addition to individual p-values, we used Hochberg's 555 step-down method to control for a family-wise-error rate at the 0.05 level. 556
Survival curves were plotted using the Kaplan-Meier method and compared 557 with the log-rank test. Bivariate correlation analysis was demonstrated as 558
Spearman's rank correlation coefficient. Where appropriate, one-way ANOVA 559 was used and pair-wise comparison using Tukey's method to adjust for 560 multiple testing was applied. Two-tailed p<0.05 was considered significant. In this study, we found that CD155 expression was significantly 576 increased in tumor tissue and associated with decreased immune response, 577 leading to poor survival in lung adenocarcinoma patients. Lung 578 adenocarcinoma cells suppressed CD8 T cell function through CD155. 579
Recombinant human CD155 protein inhibited immune response in the tumor 580 microenvironment and promoted tumor growth in a patient-derived xenograft 581 mouse model. In addition, we detected increased CD96 (co-inhibitory receptor) 582
and decreased CD226 (co-stimulatory receptor) on CD8 T cells from lung 583 adenocarcinoma patients. In a T cell-cancer cell co-culture system, IFNγ 584 production in CD8 T cells was suppressed and blocking CD155/CD96 could 585 restore IFNγ production in CD8 T cells. 586
587
Impact 588 LUAD cells suppress antitumor immune response through 589 CD155/CD96-interaction. Moreover, the inhibition effect can be reversed by 590 CD96 blocking antibody, suggesting that CD155/CD96 can serve as a 591 potential treatment target for LUAD 
